JP2023550628A - 抗原結合分子およびその使用 - Google Patents

抗原結合分子およびその使用 Download PDF

Info

Publication number
JP2023550628A
JP2023550628A JP2023530833A JP2023530833A JP2023550628A JP 2023550628 A JP2023550628 A JP 2023550628A JP 2023530833 A JP2023530833 A JP 2023530833A JP 2023530833 A JP2023530833 A JP 2023530833A JP 2023550628 A JP2023550628 A JP 2023550628A
Authority
JP
Japan
Prior art keywords
amino acid
acid sequence
seq
antigen
binding molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023530833A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023550628A5 (https=
Inventor
サマンサ ジェイ． バスフィールド，
マシュー ジェイ． ウィルソン，
Original Assignee
スカウト バイオ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by スカウト バイオ， インコーポレイテッド filed Critical スカウト バイオ， インコーポレイテッド
Publication of JP2023550628A publication Critical patent/JP2023550628A/ja
Publication of JP2023550628A5 publication Critical patent/JP2023550628A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2023530833A 2020-11-23 2021-11-22 抗原結合分子およびその使用 Pending JP2023550628A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063117383P 2020-11-23 2020-11-23
US63/117,383 2020-11-23
PCT/US2021/060369 WO2022109403A1 (en) 2020-11-23 2021-11-22 Antigen-binding molecules and uses thereof

Publications (2)

Publication Number Publication Date
JP2023550628A true JP2023550628A (ja) 2023-12-04
JP2023550628A5 JP2023550628A5 (https=) 2024-11-28

Family

ID=81709767

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023530833A Pending JP2023550628A (ja) 2020-11-23 2021-11-22 抗原結合分子およびその使用

Country Status (8)

Country Link
US (1) US20230416356A1 (https=)
EP (1) EP4247848A4 (https=)
JP (1) JP2023550628A (https=)
KR (1) KR20230118864A (https=)
CN (1) CN116981691A (https=)
AU (1) AU2021383841A1 (https=)
CA (1) CA3199586A1 (https=)
WO (1) WO2022109403A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4602073A2 (en) * 2022-11-15 2025-08-20 Purdue Research Foundation Canine pd-l1 antibody, antigen binding fragments thereof, and methods of use thereof
GB202405576D0 (en) * 2024-04-19 2024-06-05 272Bio Ltd VHH antibodies
CN121362250A (zh) * 2024-07-19 2026-01-20 普米斯生物技术(珠海)有限公司 抗il-31抗体、其药物组合物及用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014529295A (ja) * 2011-07-21 2014-11-06 ゾエティス・エルエルシー インターロイキン−３１モノクローナル抗体
WO2019183449A1 (en) * 2018-03-23 2019-09-26 North Carolina State University Methods and compositions for allergic disorders
JP2020511123A (ja) * 2017-02-24 2020-04-16 キンドレッド バイオサイエンシズ インコーポレイテッド 獣医用抗ｉｌ−３１抗体

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ME03057B (me) * 2007-12-07 2019-01-20 Zymogenetics Inc Molekuli humanizovanih antitela specifični za il-31
WO2009138494A2 (en) * 2008-05-15 2009-11-19 Ablynx N.V. Amino acid sequences directed against toll-like receptors and polypeptides comprising the same for the treatment of diseases related to toll-like receptors
JP2016522168A (ja) * 2013-04-05 2016-07-28 ジェネンテック， インコーポレイテッド 抗ｉｌ−４抗体及び二重特異性抗体及びその使用
MA40824A (fr) * 2014-10-22 2017-08-29 Saiba Gmbh Particules de cmv de type virus modifié
JP6800853B2 (ja) * 2014-12-11 2020-12-16 ピエール、ファーブル、メディカマン 抗ｃ１０ｏｒｆ５４抗体およびその使用
GB201621439D0 (en) * 2016-12-16 2017-02-01 Singapore Health Services Pte Ltd And Nat Univ Of Singapore IL-11Ra Antibodies
GB201710835D0 (en) * 2017-07-05 2017-08-16 Ucl Business Plc ROR1 Antibodies
MX2020006105A (es) * 2017-12-11 2020-11-09 Ubi Ip Holdings Inmunógenos peptídicos de il-31 y formulaciones de estos para el tratamiento y/o la prevención de la dermatitis atópica.
CA3093539A1 (en) * 2018-03-16 2019-09-19 Zoetis Services Llc Interleukin-31 monoclonal antibodies for veterinary use
US11433139B2 (en) * 2018-03-16 2022-09-06 Zoetis Services Llc Peptide vaccines against interleukin-31
US20190300610A1 (en) * 2018-03-29 2019-10-03 Hummingbird Bioscience Pte. Ltd. Vista antigen-binding molecules

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014529295A (ja) * 2011-07-21 2014-11-06 ゾエティス・エルエルシー インターロイキン−３１モノクローナル抗体
JP2020511123A (ja) * 2017-02-24 2020-04-16 キンドレッド バイオサイエンシズ インコーポレイテッド 獣医用抗ｉｌ−３１抗体
WO2019183449A1 (en) * 2018-03-23 2019-09-26 North Carolina State University Methods and compositions for allergic disorders

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
GINA M. MICHELS ET AL.: ""A blinded, randomized, placebo‐controlled, dose determination trial of lokivetmab (ZTS‐00103289)", VETERINARY DERMATOLOGY, vol. 27, no. 6, JPN6025040279, 19 September 2016 (2016-09-19), pages 478, ISSN: 0005699599 *

Also Published As

Publication number Publication date
US20230416356A1 (en) 2023-12-28
KR20230118864A (ko) 2023-08-14
AU2021383841A1 (en) 2023-06-22
WO2022109403A1 (en) 2022-05-27
CA3199586A1 (en) 2022-05-27
AU2021383841A9 (en) 2024-06-13
EP4247848A4 (en) 2025-10-01
CN116981691A (zh) 2023-10-31
EP4247848A1 (en) 2023-09-27

Similar Documents

Publication Publication Date Title
US20250354169A1 (en) Adeno-associated virus (aav) delivery of anti-fam19a5 antibodies
CN1426423A (zh) 螯合淀粉样蛋白β肽的人源化抗体
JP5596777B2 (ja) ヒトｔｗｅａｋに対する抗体とその使用
JP2023550628A (ja) 抗原結合分子およびその使用
US20230110287A1 (en) Antigen-binding molecules and uses thereof
US20250011412A1 (en) Antigen-binding molecules and uses thereof
CN118638234B (zh) 抗bdca2抗体及其制备方法和应用
US20250277060A1 (en) Antigen binding molecules and methods thereof i
AU2021366659A1 (en) Method of suppressing immune response to vector-delivered therapeutic protein
WO2024061158A1 (en) Slit2 related compositions and methods
US20260035484A1 (en) Isolated antigen binding protein and use thereof
WO2025185738A1 (zh) 靶向cxcr3的抗原结合蛋白及其应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241120

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241120

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251001

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20251223

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260227